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Abstract 
 
There is growing interest in the interaction between type 2 diabetes (DM) and tuberculosis 
(TB), but many research questions remain unanswered. Epidemiologists, basic scientists and 
clinical experts recently convened and identified priorities. This is the first of two reviews on 
this topic, summarising priority areas of research with regard to epidemiology, clinical 
management and public health. First, from an epidemiological point of view, more study is 
needed to determine the importance of transient hyperglycemia in TB patients, and on the 
importance of DM for the global epidemic of multi-drug resistant (MDR)-TB. Second, with 
regard to screening and clinical management of combined TB-DM, clinical trials and large 
cohort studies should examine the benefits of improved DM care as well as prolonged or 
intensified TB treatment to the outcome of TB-DM, and investigate cost-effectiveness of 
screening methods for DM among newly diagnosed TB patients. Third, from a public health 
and health systems point of view, the population health impact and cost-effectiveness of 
different interventions to prevent or treat DM and TB in high burden populations should be 
examined, and health systems interventions should be developed for routine TB-DM 
screening, management of DM after TB treatment completion, and better access to DM 
services worldwide. Studies are needed across different ethnicities and settings given the 
heterogeneity of metabolic perturbations, inflammatory responses, medications, and access 
to health care. Finally, studies should address interactions between TB, DM and HIV, 
because of the convergence of epidemics in sub-Saharan Africa and some other parts of the 
world.  
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Introduction 
 
Prevalence of type 2 diabetes (DM) continues to increase rapidly in low and middle income 
countries (LMIC) as a result of rapid urbanisation
1
 and nutrition transition
2
, combined with a 
genetic and epigenetic ‘mismatch’ of their inhabitants with more affluent environments
3
. 
Already, about 80% of the 415 million estimated DM cases globally are from LMICs. Diabetes 
increases the risk of many infectious diseases including tuberculosis
4
 (TB), and diabetes 
prevalence is projected to rise most steeply in regions with high TB incidence such as Sub-
Saharan Africa (SSA) over the next 30 years
5
. A high proportion of diabetes in LMICs is 
undiagnosed and diabetes screening can be more challenging during TB treatment due to 
stress hyperglycemia that might be transient
6
. Optimal TB treatment regimes for diabetic 
patients have not been established, and many issues related to DM management during TB 
treatment remain unresolved. The scale of the health systems challenges with regard to the 
interacting epidemics of TB and DM have yet to be fully realized. To address some of these 
issues, a group of international TB and DM experts convened at the National Institutes of 
Health (NIH) in May 2016 to discuss the convergent epidemics of these communicable and 
non-communicable diseases with regard to their epidemiology, underlying biological 
mechanisms and clinical management. This review provides an overview of the topics 
discussed, ending with a list of research prioirities, with Part 1 focussing on the epidemiology, 
public health and clinical aspects of the TB-DM interaction.  
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Epidemiology and public health    
 
Summary box  
• Diabetes increases risks of TB disease and poor TB treatment outcomes 
• There is a relationship between dysglycaemia and TB risk 
• Improved nutrition (and higher Body Mass Index - BMI) is protective against TB; 
hence at a population level the interplay between rising obesity and TB disease is 
unclear. At an individual level, higher BMI (without DM) may be protective but the 
development of diabetes impairs immunity to TB 
• Prevalence of DM and metabolic syndrome in HIV patients appears to be high, 
particularly among those on anti-retroviral therapies (ART) 
• The interactions among DM, HIV and TB are multi-dimentional and poorly 
understood, limiting our ability to estimate future trends for these concurrent 
epidemics 
  
Direction and magnitude of TB and DM associations 
 
The adverse effects of DM on TB incidence and outcomes are now widely accepted.  
Systematic reviews have suggested over a three-fold increased risk of TB disease among DM 
patients
7
, and a doubling of prolonged sputum positivity, TB treatment failure, death, and 
relapse
8
. However, it is important to note that the increased TB risk in patients with DM 
shows wide variation among studies, regions and populations, with risk estimates ranging 
from 0.99 to 7.83
7
. Study designs with variable case definitions and adjustment for 
confounders may explain some of these differences
9
. Moreover, biological and non-
biological factors may underlie racial and ethnic differences in the risk of diabetic 
complications including cardiovascular disease, retinopathy, nephropathy and neuropathy
10
. 
Similar factors could explain differences in DM-associated “immunopathy” leading to 
increased TB risk. Variables contributing to differential susceptibility probably include local 
host and pathogen genetics and microbiota, competing acquired risk factors like HIV, and 
environmental and behavioral factors (e.g., smoking, alcohol consumption, and exposure to 
outdoor or indoor air pollution). Poor glycemic control, which is associated with TB 
susceptibility
8
, is also a reflection of access to effective DM care
11
. Recent studies indicate 
that South India, the Pacific Islands and Mexico are particular hotspots for DM-associated 
TB.
12
 As an example, it was recently reported that 54% of newly diagnosed adult TB patients 
in Chennai, India, have DM while only 25% were normoglycemic
13
. In some Pacific islands 
approximately 40% of TB patients have concurrent DM
14
, and at the Texas-Mexico border 
region it is around 25%
15
. There is accumulating evidence that DM is associated with drug-
resistant and multi-drug-resistant TB (MDRTB)
16,17
, It is unclear to what extent growing DM 
prevalence rates contribute to the the increasing incidence of difficult-to-treat MDRTB 
globally (estimated at 580,000 in 2015)
18
.  
It is generally assumed that DM is increasing the risk of TB, rather than TB disease increasing 
the likelihood of developing DM.
9,19
 However, many studies have been unable to ascertain if 
the onset of DM pre-dated TB infection,
9
 even when it is clear that DM developed before 
active TB disease
12
. It is also plausible that TB disease may increase DM risk. A previous TB 
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diagnosis was associated with an increased risk of DM over a four year time period based on 
primary care data in the UK, though this study could have been affected by residual 
confounding
20
. In an Indian cohort study, TB patients with newly diagnosed DM had 
markedly lower glycated haemoglobin (HbA1c) values (although still abnormal) compared to 
those with known DM, suggesting that TB might, at least traniently, stimulate progression 
from intermediate hyperglycaemia to frank DM or identify those individuals who may be 
more prone to metabolic alterations or diabetes in the future
13
. However, there are no 
cohort studies following up patients who developed transient hyperglycaemia during TB 
treatment over the longer term (5-10 years), to assess their future risks of DM, need for DM 
care, and possible intervention.  
 
Pre-diabetes, transient hyperglycemia and TB 
 
Pre-diabetes reflects a continuum of insulin resistance and hyperglycaemia that are above 
“normal” but not reaching the cut-off for DM.
21
 Pre-diabetes might also be associated with 
increased risk of TB disease and adverse TB outcomes, although evidence is limited. Studies 
from both India and South Africa have found extremely high prevalence of pre-diabetes 
defined by HbA1c or oral glucose tolerance test (OGTT) among TB patients of 25%-57%
22
 
13,23
. A recent cross-sectional study among refugees arriving into the US also found increased 
prevalence of latent TB infection (LTBI) among individuals with pre-diabetes (39.1%) and DM 
(43.4%) compared to those with normal glycaemia (25.9%), with even higher prevalences for 
those who also had low vitamin D levels.
24
 Only a few studies have published data estimating 
the association between pre-diabetes and active TB; one Indonesian study found a 
significant  association between impaired fasting blood glucose (FBG) and TB (OR 4.2, 95% CI 
1.5 to 11.2)
25
, and two other studies from the US and China also reported associations of 
1.34 using OGTT
26
 and 1.14 based on impaired FBG
27
 but the US study was underpowered, 
and neither were statistically significant. Further observational evidence of the effects of 
pre-diabetes on TB risk and outcomes is needed. 
 
In low income settings DM is often undiagnosed, but results of screening tests during active 
TB may be harder to interpret due to inflammation- or stress-related hyperglycemia. Even 
though transient, this hyperglycaemia is not only associated with adverse TB outcomes
28
, 
but also a marker for future risk of type 2 DM, similar to gestational DM
29
.  
 
Population impact of DM on TB  
 
Several studies have estimated the population impact of DM on TB, often in comparison 
with other TB risk factors such as HIV, smoking, malnutrition and indoor air quality
30
. 
Generally, between 10-20% of TB is attributed to DM
31,32
, although specific settings reported 
higher risks
12
. Such studies, although mathematically simple, are hampered by conceptual 
difficulties
33
 and likely to result in inaccurate estimates of the true population impact of DM. 
This is because they are “static” and fail to account for possible higher TB transmission 
associated with DM. More dynamic models of TB and DM have been developed
34
, 
demonstrating the potential benefits of controlling DM to mitigate the burden of TB. A 
recent mathematical modelling study representing 13 countries with high TB burdens 
estimated that if the prevalence of DM continues to rise at present rates, global TB incidence 
would decline by only 8.8% and TB mortality by 34.0% by 2035. If DM prevalence stopped 
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increasing, TB would decline by 20.3% and mortality by 42.7%. Moreover, if the prevalence 
of DM increases further, the declining trends in TB incidence will be reversed entirely and by 
2035 there would be a 7.8% increase in TB incidence.
35
  All modelling studies also suffer 
from data limitations; robust estimates for all key parameters (such as associations between 
DM and LTBI) are not currently available, and may be refined in the future. Emerging 
evidence that DM is associated with MDRTB will also need to be incorporated into future 
models
16,17
. Continued attempts to refine the population impact of DM on TB are essential 
to estimate the cost-effectiveness of potential interventions focused on DM compared with 
targeting other TB risk factors
30
 or intensifying screening and case finding.  
 
Obesity, nutritional status and TB-DM 
 
Nutritional status is an important factor in the association of TB and DM
36
. Undernutrition, 
both in terms of total nutrient intake and specific micronutrients, is inversely associated with 
TB risk in observational studies
37
. Obesity on the other hand increases DM risk, but 
overweight (with higher BMI, at least up to 30 kg/m
2
) without DM appears to be protective 
against TB.
38
 In any given population, only a fraction of those individuals with high BMI will 
develop DM, and hence the population impact of rising BMI on TB is not clear, although it is 
important to note that DM risk increases at much lower levels of BMI in individuals from 
Asian countries than in the West
39
. Recent systematic reviews of macronutrient 
supplementation among TB patients have not shown treatment benefit, but there are only a 
few, small low quality trials available
40
.   
 
Specific micronutrients, as well as total calorie consumption, have been implicated in TB risk, 
but there is as yet no strong evidence that supplementation improves TB outcomes
40
. 
Vitamin D deficiency can be very common; a recent Indian study found that 100% of TB-DM 
patients are vitamin D insufficient
13
. There has been much speculation about the potential 
role of vitamin D supplementation in reducing infection risks or improving outcomes in 
patients with TB or DM with little evidence of benefit
41,42
 although better designed studies 
are underway (see for example: http://www.d2dstudy.org).  
 
Further observational studies are needed to better understand the interactions between TB 
and DM over a range of BMI values in different populations, as well as determining optimal 
BMI ranges and specific macro- or micronutrients that may be involved in reducing TB risks 
in different populations of DM patients. Further trials of the effects of micro nutrient 
supplementation on TB recurrence and LTBI reactivation may also be warranted, including 
DM patients.  
 
HIV and diabetes (and TB) 
 
Little is known about how HIV may affect the interaction between TB and DM. The 
association between TB and HIV was well recognised from the early years of the AIDS 
epidemic, with the greatest burden of TB-HIV co-infection being in SSA
43
. With mortality 
from HIV falling in SSA, and increasing prevalence of non-communicable diseases (NCDs), it 
is likely that the prevalence of DM in HIV patients is rising
43,44
. In addition, ART, especially 
protease inhibitors, increases the risks of metabolic syndrome, dysglycaemia and 
subsequently DM and cardiovascular disease
45-47
, particularly as use increases over time with 
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improved HIV survival. However, studies of HIV patients from SSA have shown substantial 
heterogeneity in DM prevalence, possibly due to differences in settings (hospital or 
community-based), methods for ascertaining DM and diagnostic cut-points used, as well as 
whether the HIV-infected participants included had already received ART
48
. Diabetes 
prevalence among cohorts of HIV patients has thus varied from 0-10% and dysglycaemia 
prevalence from 2-35%, respectively
48
. There may be a different assocation between TB and 
DM in people with HIV
49
. A Tanzanian cohort study demonstrated a fivefold increased risk of 
early mortality among HIV-uninfected patients, but only a twofold increase among HIV co-
infected patients.
50
 The precise explanations for this are uncertain but the very strong 
association between HIV and TB may suppress that of DM, given that HIV is associated with 
reduced long term survival, poorer nutritional status, and lower BMI, all reducing the 
opportunity for DM to develop. Co-trimoxazole prophylaxis for infections in HIV-infected 
patients also has hypoglycaemic effects, and may be protective against DM
51
. Despite the 
potential public health importance, there is limited modelling or projections of the likely 
future of DM, HIV and TB multi-morbidity in SSA or elsewhere. There is also little evidence 
for the optimal screening and management of DM in HIV patients, although it is thought that 
DM is currently under-diagnosed and improperly managed in HIV as well as in TB patients.  
 
Prevention of DM 
 
To date, efforts to control the converging epidemics of DM and TB have focused on 
detection and treatment rather than DM prevention. Prevention of DM is very difficult. In 
one of the largest clinical trials, the Diabetes Prevention Program (DPP), a labour intensive 
lifestyle change programme and use of metformin showed a 31%-58% reduction in short 
term DM incidence, but long-term follow-up revealed that DM was merely delayed
52
 and 
such intensive, individually focused programs could not be generalised in low income 
settings. More effective approaches may include environmental change, or fiscal and 
legislative change (e.g., taxes on fast food and sugar and improved community-planning 
laws), but there is limited evidence for their effectiveness
53,54
. Unfortunately, prevention of 
NCDs has a low priority in TB-endemic settings due to low awareness and a high burden of 
communicable or acute illnesses. Besides primary prevention, early detection and treatment 
of DM, and interventions to lower HbA1c in patients with diabetes (lifestyle interventions or 
medication) could reduce TB risk, although evidence for this is limited
55
. 
 
Detection and clinical management of TB-DM 
 
Screening TB patients for DM and DM patients for TB  
 
Detection of combined TB and DM is a first step towards better disease management. The 
prevalence of DM among TB patients varies across settings but is generally >10% and often 
much higher, especially in older age groups, with up to 50% of cases newly detected on 
screening
22,56,57
. Diabetes screening in TB patients is not straightforward. Diabetes risk 
scores and different laboratory measurements like fasting or random blood glucose levels, 
OGTT and HbA1c need to be evaluated in different settings and patient populations
58
. There 
is also a lack of clarity regarding the optimal timing of DM screening, as active TB can induce 
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insulin resistance and stress-hyperglycemia.
28
 Ongoing TANDEM studies have demonstrated 
the heterogeneity in diagnostic accuracy of screening algorithms among different 
populations
59
. In general, point of care HbA1c and blood glucose testing, in combination 
with age, diagnosed the most DM patients, but the sensivity and specificity of these 
approaches were highly variable
59
.  
 
The yield of TB screening among patients with DM is much lower. Where TB prevalence is 
<25 per 100,000, at least 1000 people with DM would need to be screened to detect a single 
additional case of TB.
60
 In contrast, in countries like India, screening 90-350 people with DM 
would be expected to yield one or more TB cases
61
. Risk stratification (including background 
TB prevalence, history of TB, DM “severity”, smoking, socio-economic variables, and 
presence of cough) could help prioritise a subgroup of DM patients for TB screening. Again, 
more data are needed regarding the most optimal screening tools (questionnaires, 
microbiological tests and chest X-rays) for TB in diabetes or general medicine clinics. New 
developments, such as computer-assisted X-ray reading
62
, may help facilitate screening DM 
patients for TB in some high incidence settings; but, at present, this is highly unlikely to be a 
cost-effective approach.  
 
Screening patients with DM for latent TB infection (LTBI) 
 
Screening and treatment of LTBI has been advocated for groups at high risk of developing 
active TB disease like HIV-infected individuals. This approach may theoretically help progress 
towards TB elimination in some higher-income settings, where a high proportion of TB cases 
arise from reactivation among foreign born migrants with DM, suggesting that this group 
may be an appropriate population on which to focus LTBI screening.
60,63
 LTBI diagnosis is 
very important and should precede treatment. However, the few studies in the literature on 
the impact of DM on TB are small and show contradictory results in terms of the 
QuantiFERON® test in patients with DM
64-66
. Immune-based tests do not predict TB disease 
very well. Currently there is no evidence that LTBI treatment is effective among people with 
DM, nor if it leads to more isoniazid (INH) hepatotoxicity, or lower drug levels. No cost- 
effectiveness studies have been done, and it is unclear how to counsel providers to test and 
treat LTBI, or how to encourage DM patients to accept and adhere to LTBI treatment.  
 
Clinical management of combined TB and DM 
 
Most studies of TB and DM have focused on prevalence or screening and there are very little 
data to guide clinical management of patients with the two diseases. A number of questions 
remain to be answered
67
 (text box).  
 
Text box 
- Should we adjust TB treatment in dose or duration? Should we follow TB-DM 
patients after completion of TB treatment given the higher risk of recurrent TB? 
- How important is glycemic control for improving TB outcomes in TB-DM? 
- Should we use insulin or metformin (or other glucose-lowering medications) for 
glycemic control in TB-DM patients?  
- Is there more hepatotoxicity in TB-DM? Should we monitor TB treatment more 
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intensively in a TB-DM patients? 
- What drug-drug interactions are relevant for treating combined TB-DM?  
- Can we explain the higher mortality seen in TB-DM in some settings? Should we 
consider adjuvant anti-platelet or lipid-lowering treatment?  
- How should TB-DM patients be counselled with respect to lifestyle changes?  
- How should care for TB-DM patients be coordinated, and how should DM care be 
continued after completion of TB treatment?  
Patients with DM are generally more likely to experience TB treatment failures and 
recurrences
16
. Observational studies suggest that prolonged treatment may improve 
outcome
68
. Some studies found lower concentrations of rifampicin and other TB drugs in 
diabetics
69
 suggesting higher drug dosages
70,71
 may be of benefit. This could however lead to 
more drug toxicity and treatment complications, especially in TB-DM patients who are 
generally older and often have pre-existing liver or kidney disease. There is now good 
evidence that diabetes is a risk factor for drug resistant TB
17
 but there are no systematic data 
on the use of second-line TB drugs in individuals with DM. 
There is also a lack of evidence to guide DM management in TB-DM patients. Diabetes is not 
a homogeneous disease. Patients have different levels and duration of hyperglycemia, 
hyperlipidemia, inflammation (‘metaflammation’), body composition, cardiovascular risk 
profiles, medications, complications, comorbidity and ethnic backgrounds. Achieving good 
glycemic control in TB-DM is challenging because of inflammation, drug-drug interactions 
and other issues
6
 and the benefit of tight or even improved glucose control during TB 
treatment remains to be determined. Rifampicin strongly increases the metabolism of most 
oral antidiabetic drugs
6
 while insulin, advocated in guidelines for TB-DM, has several 
drawbacks including its insecure availability in many settings
72
, risks of hypoglycemia, and 
need for drug-injection and self-measurement of blood glucose. Metformin, a widely used 
oral drug for type 2 DM, probably has no drug-interaction with rifampicin and does not 
typically induce hypoglycemia. However, its safety and tolerability in TB patients has not 
been investigated.  
 
Drug-drug interactions may occur during absorption, distribution, liver metabolism and 
elimination from the kidney. Several drug-drug interactions are of concern in managing 
patients with TB and DM and/or HIV. Rifampicin as a primary TB drug can affect the efficacy 
of many other drugs, including HIV drugs and most oral DM drugs
6
. Dolutegravir, one of the 
most widely prescribed anti-HIV drugs, blocks metformin elimination and thus doubles 
metformin exposure
73
, which may lead to lactic acidosis. All of these interactions show large 
inter-individual variability and there is a lack of pharmacokinetic studies in this field. 
 
Besides glycemic control, other treatment options may have to be considered in TB-DM 
patients. For example, studies in Taiwan
74
 and Tanzania
50
 showed increased early (<3 
months) mortality which could be caused by cardiovascular events. If true, there should be 
more awareness regarding cardiovascular risk management, with the possible use of anti-
platelet, lipid-lowering and anti-hypertensive treatments, as well as lifestyle interventions, 
especially smoking cessation
6
. Timing of interventions targeting TB and DM should also be 
examined. All of these questions could be addressed in pragmatic clinical trials, but to our 
knowledge, so far only one trial by the TANDEM network, is ongoing (NCT02106039).  
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Health systems challenges  
 
Health systems issues in jointly managing TB and DM may be among the greatest challenges 
to overcome
75
. Continued management of DM by itself is a particular problem in most LMICs 
because of lack of health insurance coverage, and the fact that health systems in these 
settings are not designed for management of chronic conditions  such as DM
76
. While 
directly observed short-course treatment for TB (DOTS) and WHO funding have substantially 
improved uptake and outcome of TB treatment, no such equivalents for DM care exist in low 
income settings, and hence levels of DM detection and management are generally poor
37
. 
Moreover, political will or comprehensive national strategies are often lacking, management 
guidelines are not widely available, and staff may be scarce or poorly trained. The general 
trend towards an expansion of the private sector as a provider for NCD care in urban areas 
often exacerbates inequality, leaving an underclass of the most deprived DM patients 
accessing increasingly rundown state services
75
; such groups are also at highest risk of TB. 
Relatively few lower income countries have developed comprehensive strategies to reduce 
the upstream determinants of DM such as obesity, poor diet and physical inactivity, with 
little inter-sectoral collaboration
77
. This is despite alarming predictions of rising DM 
prevalence and associated costs. Some countries (e.g., India, China) have established policies 
and mechanisms for screening TB patients for DM, including establishing blood glucose 
testing and in some cases providing insulin availability in TB clinics
78
,
79
 but generalising these 
processes across the entire country has not yet been successful.  
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Summary and future research priorities 
DM is an increasingly important factor contributing to the global TB epidemic. There are a 
number of outstanding questions with regard to the epidemiology of the interaction 
between TB and DM, its clinical management and public health aspects.  
 
With regards to epidemiology, better designed epidemiological studies and clinical cohorts 
are required to better understand the importance of transient hyperglycemia, magnitude of 
the association between DM and drug resistant TB, and potential impact of rising DM 
prevalence on “difficult to treat” MDRTB. 
With regards to clinical management, clinical trials or large cohort studies should examine 
the benefit of prolonged or intensified TB treatment for TB-DM patients, and clinically 
relevant interventions with respect to DM (e.g., best approaches to glycemic control, follow-
up of patients with transient hypergylcaemia, management of cardiovascular risk, optimal 
timing and methods of screening for DM, etc.) for the full range of TB-DM patients and 
across different ethnicities.  
With regards to public health, more refined mathematical and economic models are 
required to estimate the costs and potential impact of different interventions (such as 
screening TB patients for DM and vice versa, intensified management, and treatment of 
LTBI) on the TB epidemic in different populations.  Cost-effectiveness analyses are entirely 
lacking at present, and our list of priorities may need to be re-considered as such studies 
become available.  
 
Diabetes is not a homogeneous disease (as is the case for TB). Differences in duration and 
severity of hyperglycemia, hyperlipidemia, inflammation (‘metaflammation’), body 
composition, cardiovascular risk profiles, smoking behavior, medication, complications and 
co-morbidities, ethnic backgrounds, socio-economic status and access to healthcare 
probably account for variable effects of DM on TB risk and TB treatment outcomes. 
Furthermore, HIV is becoming an increasingly important co-factor in this interaction, 
especially with the increasing prevalence of DM in Sub-Saharan Africa. This should be taken 
into account in future research.  
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